Liposomal Irinotecan for Advanced Colon or Rectal Cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new chemotherapy drug called liposomal irinotecan as a second treatment for metastatic colorectal cancer (cancer that has spread beyond the colon or rectum). You would be eligible if your cancer progressed after your first chemotherapy treatment and you're in good enough health to receive more treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Between 18 and 75 years old
- Histologically confirmed metastatic colon or rectal adenocarcinoma (cancer that has spread)
- Previously received first-line oxaliplatin-based chemotherapy
- At least one measurable tumor lesion visible on imaging
- Good organ function (liver, kidneys, heart, bone marrow) based on recent blood and imaging tests
- Expected to live at least 3 months from enrollment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of several cancer drugs (irinotecan, capecitabine, bevacizumab, and camrelizumab) in people with metastatic colorectal cancer who have already tried at least one prior treatment. The goal is to see if these drugs work better together for patients who don't have certain genetic features.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This trial tests a new type of chemotherapy (irinotecan liposomes) as a first treatment for metastatic colorectal cancer that has not been treated before. It focuses on patients with specific genetic changes (RAS or BRAF V600E mutation) or right-sided colon cancer, and looks at how well the drug works.
This trial tests a new form of chemotherapy (liposomal irinotecan) combined with two standard drugs (5-FU and leucovorin) and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and helps people live longer.
This trial tests a new form of the chemotherapy drug irinotecan (called irinotecan liposome) combined with two other chemo drugs and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that has already been treated with oxaliplatin. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new version of the chemotherapy drug irinotecan (called liposomal irinotecan) combined with bevacizumab, a targeted therapy, for people with colorectal cancer that has spread and has stopped responding to irinotecan. The goal is to see if this combination can control the tumor better.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.